+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, and how the body processes the drug JPH034 in healthy adults aged 18 to 50 years. This Phase 1 study is randomized, double-blind, and placebo-controlled and also includes a pilot evaluation of how food affects the drugs behavior in the body. The study aims to identify any side effects and understand how JPH034 and its main metabolite, M1, are absorbed and eliminated. Participants will be randomly assigned to receive a single oral dose of JPH034 or a placebo in different dose groups. The single-ascending dose SAD groups receive one dose under fasting conditions and stay confined for 48 hours for monitoring. A subset of participants will return for a pilot food effect evaluation, receiving JPH034 after a high-fat meal to study how food influences drug exposure. Safety review committees will monitor data to determine dose escalation and safety. During the study, participants undergo physical exams, vital sign checks, ECGs, and laboratory tests to monitor safety. Blood and urine samples are collected to measure drug levels up to 96 hours after dosing. Follow-up visits occur 7 to 9 days later to check for adverse events and overall health. The study includes detailed safety assessments such as heart rate, blood pressure, respiratory rate, body temperature, and ECG QTc intervals to ensure participant safety throughout the trial.

Age: 18Years - 50YearsAll GendersPhase 1
1 location
S

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the safety and tolerability of mirikizumab LY3074828 when given as a single injection compared to two separate injections under the skin in healthy adult volunteers aged 18 to 65 years. The study is conducted in a Phase 1 setting to understand how the body processes the drug through blood tests. The trial is sponsored by Eli Lilly and Company and includes healthy participants without significant medical conditions. Participants will receive mirikizumab administered subcutaneously in one of three experimental arms. The study is randomized and open-label, comparing different injection methods of the same drug. The treatment period is followed by monitoring to assess pharmacokinetics, including maximum concentration and drug exposure over time. Throughout approximately 15 weeks, volunteers will undergo medical evaluations such as physical exams, laboratory tests, ECGs, and vital sign monitoring. Blood samples will be collected to measure drug levels and how the body absorbs and eliminates the study medication. Safety and tolerability assessments will continue during this period to ensure participant well-being.

Age: 18Years - 65YearsAll GendersPhase 1
5 locations
R

Actively Recruiting

Healthy Volunteer

Researchers are evaluating ACCG-2671, a nonpeptide dual amylin and calcitonin receptor agonist, in a first-in-human study to assess its safety, tolerability, and how the body processes the drug. The study includes healthy adults and adults with obesity and investigates the impact of food on the drugs effects. This randomized, double-blind trial is sponsored by Aconcagua Bio, Inc. The study has three parts Part 1 tests single ascending oral doses of ACCG-2671 or placebo in healthy participants Part 2 assesses the effect of food on a single dose in healthy participants under fasted and fed states and Part 3 evaluates multiple ascending daily doses over 84 days in adults with obesity, including those on stable injectable GLP-1RA treatment. Safety committees review data before increasing doses. Participants will undergo screening and then receive assigned doses or placebo, with monitoring including clinical evaluations, laboratory tests, vital signs, and ECGs over specified periods ranging from 17 to 112 days depending on the study part. Researchers track adverse events and changes in various blood and heart function measures. The study runs from December 2025 to April 2027, with detailed follow-up during and after dosing periods.

Age: 25Years - 75YearsAll GendersPhase 1Phase 2
6 locations